Ozari vs NovoCare Pharmacy: Wegovy's $199 Intro Price Lasts Exactly Two Fills

Two fills. That is how long NovoCare Pharmacy's $199-per-month Wegovy price lasts for new self-pay patients, per Novo Nordisk's published terms as of August 2026. The offer covers the first two monthly fills through December 31, 2026, then the pen price moves to $349 per month. The pill version undercuts both: Wegovy tablets have been listed at $149 per month for certain doses. For a branded, FDA-approved semaglutide sold straight from the manufacturer's pharmacy, these are the lowest published cash prices Wegovy has ever carried.

Before any math: NovoCare Pharmacy sells Wegovy — FDA-approved branded semaglutide. Ozari's flat-priced program uses compounded semaglutide, which is not FDA-approved. Different products. This comparison is about monthly cost and access, not equivalence.

What NovoCare Pharmacy Publicly Lists

From novocare.com's Wegovy pharmacy page as of August 2026:

• Injection pens, self-pay: $199/month for each of the first two monthly fills for patients new to the program (offer through December 31, 2026), then $349/month for the 0.25 mg through 2.4 mg doses. Wegovy HD (7.2 mg) is $399/month. One month equals one box of four pens.
• Tablets, self-pay: $149/month for the 1.5 mg and 4 mg doses; the 4 mg price holds until August 31, 2026, then becomes $199/month. One month equals one bottle of 30 tablets.
• With commercial insurance that covers Wegovy: pay as little as $25/month, capped at $100/month in savings.
• No membership fee and no copay card needed. Free home delivery through named pharmacy partners — CoAssist Pharmacy and CenterWell Pharmacy — or local pickup. FSA/HSA cards accepted. A 90-day supply option exists.
• A prescription is required. NovoCare is a pharmacy channel, not a clinic; your provider sends the script, and any visit costs sit outside these prices.

Novo Nordisk states it can modify or cancel these programs at any time, so verify current pricing directly with NovoCare.

How the Models Compare

NovoCare's appeal is straightforward: authentic Wegovy from Novo Nordisk's own channel, transparent per-dose pricing, named dispensing pharmacies, and an oral option no compounder can match. If you want the FDA-approved product without insurance, this is the manufacturer's floor price — and the $149 tablet tier is genuinely aggressive.

The structure has edges. The $199 pen price is an introduction, not a rate — it expires after two fills. Standard pens settle at $349, and the 7.2 mg pen at $399. The prescription and any provider visits are your problem to arrange and pay for. Promotional windows carry dates, and dates pass.

Ozari's model is one flat number with care included: compounded semaglutide at $86/mo starter, $145/mo quarterly, $175/mo monthly; compounded tirzepatide from $125/mo. Provider review comes before any prescription. No membership fee, HSA/FSA accepted, licensed 503A US compounding pharmacies, LegitScript certified, all 50 states via intake confirmation. Ozari also runs branded pathways — Wegovy included — for patients who want the FDA-approved product. The caveat stays constant: compounded semaglutide is not FDA-approved, and the price gap is the price of that difference.

The 12-Month Math

NovoCare, injection pens, new self-pay patient, offers as listed:

• Fills 1–2: $199 × 2 = $398
• Fills 3–12: $349 × 10 = $3,490
• Year one: $3,888 — before any provider-visit costs.

NovoCare tablets at the listed $149: $149 × 12 = $1,788, if your prescribed dose stays within the offer terms; note the 4 mg tier is listed to rise to $199 after August 31, 2026, which would push a 4 mg year toward $2,138. Verify current tablet terms directly with NovoCare.

Ozari, compounded semaglutide starter then quarterly: $257 (starter) + ($145 × 9) = $1,562 all-in.

So: Ozari runs about $2,326 under NovoCare's pen path in year one, and roughly $226 under the tablet path at its most favorable listed pricing — a much closer race than most branded-versus-compounded matchups.

A note from our clinical team: Wegovy pens come in fixed strengths, one box per month, so a dose change is a pharmacy event rather than a syringe adjustment. When price windows move — and NovoCare's do — we see patients tempted to climb doses faster to catch an offer, or to linger at a starter strength because it's cheaper. Neither is how titration should be decided. Escalate on tolerance and response, and make sure each step is documented, so any future switch of pharmacy or program starts from a clean record.

Key Comparison Table

Red Flags — Avoid These Providers

How to Cancel NovoCare

NovoCare Pharmacy is a per-fill, self-pay channel, not a subscription — so there is no membership to cancel and no recurring charge that continues on its own. Each fill is paid for when you order it. To stop treatment, decline or skip the next fill and ask your prescriber to cancel any refills still on file with NovoCare Pharmacy, so an unwanted order isn't processed later. If an order has been paid but not shipped, contact NovoCare promptly; once medication ships, pharmacy rules generally make it non-returnable and non-refundable. Two program-terms points matter if you might come back. Per Novo Nordisk's published terms as of August 2026, the company reserves the right to pause or terminate enrollment in its self-pay and savings programs, and the intro prices carry expiration dates — so stopping now doesn't guarantee re-entry later at the same rate, or at all. Keep written or screenshot confirmation of any canceled order or refill. Ozari publishes its cancellation terms at https://www.ozarihealth.com/refund-policy

Frequently Asked Questions

How much is Wegovy through NovoCare Pharmacy without insurance?

As of August 2026, NovoCare has listed pens at $199/month for a new patient's first two fills, then $349/month for standard doses and $399 for 7.2 mg. Tablets start at $149/month. Verify current pricing directly with NovoCare.

Does the $199 price last all year?

No. Per the published terms it covers two monthly fills for patients new to the program, through December 31, 2026. After that, standard-dose pens bill at $349/month.

Is Wegovy the same as Ozari's compounded semaglutide?

No. Wegovy is FDA-approved branded semaglutide from Novo Nordisk. Compounded semaglutide is prepared by compounding pharmacies for individual prescriptions and is not FDA-approved. They are different products.

Does NovoCare include the doctor visit?

No. A prescription from a licensed provider is required, and visit costs are separate. Ozari includes provider review in its flat price.

What does a year of each cost?

NovoCare pens: $398 + $3,490 = $3,888 at listed prices. NovoCare tablets: $1,788 at the $149 tier. Ozari compounded semaglutide: $1,562 ($257 starter, then $145 × 9), medication and provider review included.

Can I get branded Wegovy through Ozari?

Yes. Ozari offers branded Wegovy, Ozempic, Mounjaro, and Zepbound pathways alongside its compounded programs, for patients who prefer the FDA-approved product.

Do I need to cancel NovoCare?

No — it's a per-fill pharmacy, not a subscription. Stop by skipping the next fill and asking your prescriber to cancel remaining refills at NovoCare Pharmacy. Note that Novo Nordisk can pause enrollment and its intro prices expire, so returning later at the same rate isn't guaranteed.

This article is for informational purposes only and is not medical advice. Wegovy is an FDA-approved medication; compounded semaglutide and tirzepatide are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. Always consult a licensed healthcare provider before starting, stopping, or switching any medication. Ozari Health connects patients with licensed independent providers who determine whether treatment is appropriate. Pricing reflects publicly listed figures as of August 2026 and may change; confirm current pricing directly with NovoCare.

Sources

• https://www.novocare.com/pharmacy/wegovy.html
• https://www.novocare.com/eligibility/obesity-pharmacy.html
• https://www.novocare.com/content/dam/novonordisk/novocare/redesign/pdf/Wegovy_Price_Guide.pdf
• https://www.ozarihealth.com/true-cost/novocare
• https://www.ozarihealth.com/compounded-semaglutide
• https://www.ozarihealth.com/compounded-tirzepatide
• https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
• https://huggingface.co/datasets/Ozarihealth/glp1-telehealth-pricing-2026